Oregovomab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CA125 |
| Clinical data | |
| Trade names | OvaRex |
| Identifiers | |
| CAS Number | 213327-37-8  |
| ATC code | none |
| KEGG | D05269  |
| Chemical data | |
| Molecular mass | ca. 150 kDa |
| (what is this?) (verify) |
|
Oregovomab (marketed under the trade name OvaRex) is a mouse monoclonal antibody it binds to the antigen CA125, a carbohydrate antigen. It is designed for the treatment of ovarian cancer.[1]
This drug was developed by AltaRex Corp.
Adverse drug effects
Lua error in package.lua at line 80: module 'strict' not found.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Oregovomab, American Medical Association.
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles using small message boxes
- Monoclonal antibodies for tumors
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
